LGC’s SARS-CoV-2 ultra-high throughput End-Point PCR test EUA authorised by FDA

News - Nexar™-based workflow enables simple, scalable, and cost-effective COVID-19 testing

27 April 2022

LGC’s new state-of-the-art site in Oxford will deliver critical diagnostics solutions and research

News - Facility will serve as home of The Native Antigen Company and an advanced workflow applications laboratory for LGC Biosearch Technologies

16 September 2022